01 — Evidence
Evidence Summary
Piperlongumine's evidence has an unusual shape: a deep, widely replicated laboratory and animal mechanism sitting on top of a complete absence of human clinical data. No cancer trial has ever tested it, and there is no human pharmacokinetic study — so read the tiers below from the bottom up, and treat the concentration question as unresolved.
Human
Clinical Record
No trials; a documented absence
No completed interventional trial has tested piperlongumine in cancer patients, and no human pharmacokinetic or metabolism study exists — every exposure figure on this page is from animals or predicted.
- No registered cancer trial uses piperlongumine as the studied drug
- In the trial registry it appears only in exclusion lists of unrelated studies, never as a studied drug
- No human study has measured how much reaches the bloodstream, or how it is broken down
Animal
Preclinical Signal
Tumor models across many cancers
Pure piperlongumine has slowed tumor growth in animal models of many different cancers, generally by raising oxidative stress inside the tumor, and was well tolerated in mice.
- Suppressed growth in pancreatic, lung, gastric, head-and-neck, bladder, glioblastoma and other tumor models
- Effective doses were given by injection, not by mouth, in nearly every study
- A two-month oral course produced no weight loss and no organ toxicity in mice
In Vitro
Cell Model Data
Cancer-selective oxidative killing
Piperlongumine's most replicated finding is that it kills cancer cells while sparing normal cells, by raising reactive oxygen species through the antioxidant enzymes tumors depend on.
- Spared normal cells at concentrations that killed cancer cells, across several tumor types
- Disabled the antioxidant enzymes GSTP1 and thioredoxin reductase 1
- Its best-replicated effects were reversed by antioxidants such as N-acetylcysteine
Human
Clinical Record
There is no human oncology evidence for piperlongumine, and this is a documented absence rather than an untested assumption. No completed interventional trial has studied it in cancer patients: a search of the clinical-trial registry returns no study with piperlongumine as an assigned intervention. It surfaces only in the exclusion criteria of unrelated trials — for example the senolytic washout list of an orthopaedic study — never as a drug that is dosed.[39]
Continue reading — full research detail+
There is also no human pharmacokinetic or metabolism study. A dedicated metabolism paper states outright that no study of piperlongumine's metabolism in the human body exists, and characterizes its handling only in isolated human liver enzymes.[5] Every exposure figure discussed under Pharmacokinetics and Administration below is therefore from rodents or predicted from laboratory systems, never measured in a person.
The one human-cell finding worth flagging points the other way from a benefit: in primary human T cells, piperlongumine has been reported to suppress effector T-cell activation and shift the balance toward regulatory T cells, through the same oxidative mechanism it uses against tumor cells — the authors framed it as a candidate immunosuppressant.[40] This is a mechanistic observation in isolated cells, not a clinical outcome, and its practical implications are discussed under Safety Profile and Co-Dosing.
Signal maturity: the human tier is empty of efficacy evidence by fact, not by omission — no trial, no human PK. This is the single most important limit on how the animal and cell findings below should be read: an effect shown in a dish or a mouse is not evidence it can be reached, safely, in a person.
Animal
Preclinical Signal
Pure piperlongumine has been reported to slow tumor growth across an unusually wide range of animal cancer models — pancreatic,[6] head-and-neck,[25] gastric,[26] bladder,[12] lung,[24] glioblastoma,[29] multiple-myeloma[4] and colorectal[16] among them — generally by raising oxidative stress inside the tumor.
Continue reading — full research detail+
The doses that worked were in the low-milligram-per-kilogram range and were almost always given by injection, not by mouth: for example, intraperitoneal piperlongumine at 30 mg/kg/day slowed a pancreatic xenograft while leaving body weight unchanged and producing PARP cleavage — a cell-death marker — directly in the excised tumors,[6] and 4 mg/kg/day slowed a head-and-neck xenograft.[25] The one oral antitumor study cited here used a nanoemulsion — at 10 mg/kg it suppressed melanoma growth by roughly 75%[3] — although a simpler oral solution of the compound was also absorbed, so enhanced formulations raise exposure rather than turn none into some.
Tolerability in these studies was good. In the melanoma study, a 60-day oral course produced no weight loss, normal liver and kidney blood panels, and no organ damage on histology.[3] The breadth is genuine — but abstracts rarely give exact tumor-reduction figures, and a recurring pitfall in this literature is that several "piperlongumine" in-vivo reports actually test chemical derivatives or metal complexes of the molecule rather than the parent compound; those are not credited here.
Signal maturity: the animal evidence is broad and consistent for tumor-growth suppression, and tolerability looks favorable at the doses used. Its ceiling is that the effective doses were reached by injection in most studies, and none of it establishes what an oral human dose would need to be — or whether it could be reached — because no human PK study exists.
In Vitro
Cell Model Data
Piperlongumine's deepest and most replicated finding is that it selectively kills cancer cells while sparing normal cells, by raising reactive oxygen species — and that this works because it disables the two enzyme systems tumor cells rely on to buffer oxidative stress, glutathione S-transferase pi-1 (GSTP1) and thioredoxin reductase 1 (TrxR1).
Continue reading — full research detail+
The selectivity has been shown in independent systems. In head-and-neck cancer, piperlongumine depleted reduced glutathione and raised its oxidized form in cancer cells but not in normal oral cells, which tolerated concentrations up to 15 µM.[1] In acute myeloid leukemia, it killed CD34+ leukemia stem/progenitor cells while sparing healthy blood-forming progenitors.[2] The molecular basis is inhibition of GSTP1[1,14] and direct inhibition of TrxR1.[13] Not all of its activity is downstream of oxidative stress, though: piperlongumine has also been reported to directly destabilize microtubules — depolymerizing them in an isolated-tubulin assay and in breast cancer cells[51] — one of several target-level actions (alongside its direct STAT3 binding) that a purely reactive-oxygen account does not capture.
Typical cytotoxic concentrations sit in the low-micromolar range — roughly 4 to 15 µM across these studies. That number matters because, with no human pharmacokinetic study, there is no evidence any oral human exposure could reach it; the best available exposure figure is a mouse total-plasma peak of about 2 µM, which already sits at or below most of these effective concentrations (see The Concentration Gap). A caveat runs through many of these studies: the killing is driven by oxidative stress and, in the studies that tested it, was abolished when cells were pre-treated with the antioxidant N-acetylcysteine.
Signal maturity: the cancer-selective oxidative-killing mechanism is the compound's deepest and most reproduced finding, replicated across many independent laboratories and cancer types. Its ceiling is the concentration question: the mechanism is real, but whether the effective concentration is reachable in a person is unknown and, on the mouse data, doubtful.
Advertisement
02 — Pathways
Pathway Interaction Profile
Piperlongumine engages several biological pathways relevant to tumor behavior, grouped below by the functional role each one supports. A single thread runs through almost all of them — a pro-oxidant, redox-stress push — and every role is scored partial, because the evidence is preclinical and the concentrations involved have never been shown to be reachable in a person. Further down, a separate set of preclinical findings concerns the body's own resilience during cancer treatment.
Piperlongumine's Contain classification rests on reported suppression of the NF-κB inflammatory-survival switch and of the invasion and migration machinery cancer cells use to spread. The mechanisms are largely from cell studies, with animal corroboration in a bladder model — and, like everything on this page, at concentrations shown only in the laboratory.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
Piperlongumine has been reported to suppress NF-κB by binding its activating kinase (IKK) directly at cysteine-179 — mutating that residue abolished the effect — which blocks IκBα phosphorylation and downregulates the NF-κB survival, proliferation and invasion genes Bcl-2, survivin, c-Myc, cyclin D1, COX-2, MMP-9 and VEGF.[7] In prostate cancer cells the same NF-κB suppression reduced invasion and was completely reversed by adding glutathione, confirming it is oxidative-stress-driven;[8] in breast cancer cells piperlongumine lowered IKKβ and blocked p65 nuclear entry, with the antioxidant NAC preventing the effect.[9] This NF-κB evidence is in vitro; the role's animal corroboration comes from the bladder model below.
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
Piperlongumine has been reported to inhibit cancer-cell migration selectively over normal astrocytes in glioblastoma, through oxidative-stress-dependent p38/JNK signaling, with every effect abolished by NAC.[10] It also inhibited TGF-β-induced epithelial–mesenchymal transition by downregulating the transcription factors Snail1 and Twist1 and restoring E-cadherin, reducing migration and invasion.[11] In bladder cancer this extended in vivo: piperlongumine suppressed tumor growth and EMT while lowering Slug, ZEB1 and N-cadherin[12] — the animal corroboration behind Contain's partial score.
Piperlongumine's Starve classification is its most distinctive: rather than cutting off a metabolic fuel, it taxes the redox-buffering systems a cancer cell needs to survive its own oxidative load. This is the mechanism most consistently reproduced across the literature, and the reason its cytotoxicity is selective — but the effective concentrations remain preclinical.
Redox Buffering Taxation (Controlled)
Research concerning tumour-cell redox buffering and vulnerability to oxidative pressure, separate from host redox protection.
NADPH production & redox balance
Piperlongumine has been reported to inhibit glutathione S-transferase pi-1 (GSTP1) and the wider glutathione antioxidant system, depleting reduced glutathione in cancer cells but not in normal cells.[1] The mechanism is subtler than simple covalent binding: structural and mass-spectrometry work found piperlongumine does not directly label GSTP1 — instead a hydrolysis product of the molecule, conjugated to glutathione, occupies and blocks the enzyme's active site, so piperlongumine behaves like a prodrug for its own GSTP1 inhibitor.[48] Other groups treat GSTP1 as an established piperlongumine target and show that combining it with a thioredoxin-reductase inhibitor is synergistic to nanomolar potency in glioblastoma stem cells.[14] It has also been reported to directly inhibit thioredoxin reductase 1 (TrxR1) — the second major antioxidant system — driving oxidative-stress-mediated ER stress and mitochondrial dysfunction, and reducing tumor TrxR1 activity and tumor burden in a gastric model.[13] Adding piperlongumine to oxaliplatin inhibited TrxR1 further, with xenograft corroboration and full reversal by NAC.[36] One dissenting study argues glutathione depletion is not itself the toxic step and that the distinctive action is direct hydrogen-peroxide elevation — which also explains why some cell lines resist.[15]
Piperlongumine's Weaken classification covers reported suppression of core growth-signaling and survival programs, plus a distinctive selective action on senescent cells. Several of these carry animal corroboration; none has a human pharmacokinetic anchor.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
PI3K–AKT–mTOR (signaling)
In colon cancer, piperlongumine has been reported to target Ras and PI3K, suppressing downstream Akt/NF-κB, c-Myc and cyclin D1, arresting the cell cycle at G2/M and triggering mitochondrial apoptosis — shown in a chemically induced mouse colon-carcinogenesis model without liver or kidney toxicity.[16] In docetaxel-resistant lung cancer it suppressed PI3K/Akt/mTOR and inhibited xenograft growth.[17]
JAK/STAT (STAT3)
Piperlongumine has been reported to be a direct STAT3 inhibitor: it blocked STAT3 phosphorylation and the binding of STAT3 to its target ligand without acting through upstream kinases, and caused regression of breast-cancer xenografts.[18] In non-small-cell lung cancer it reduced active STAT3 by at least half and inhibited A549 xenograft growth;[19] in gastric cancer it suppressed JAK1/2–STAT3 and reduced invasion and migration;[20] and in multiple myeloma it bound STAT3 at a different cysteine, reduced bortezomib resistance, and prolonged survival in a disseminated-myeloma mouse model.[4]
Hippo / YAP–TAZ
In triple-negative breast cancer, piperlongumine has been reported to activate Hippo signaling and lower the growth-driver YAP, in turn downregulating endothelin-1 and the chemokine CXCL2, reducing invasion and the activation of cancer-associated fibroblasts, and inhibiting tumor growth and fibroblast infiltration in a mouse model.[50] This is a distinct, non-redox target-level mechanism from the oxidative-stress theme running through the rest of this profile.
Attrition Pressure
Research concerning cellular stress vulnerability and net tumour-cell attrition under sustained conditions.
Cellular senescence & SASP
Piperlongumine has been reported to act as a senolytic — selectively killing senescent cells by binding oxidation-resistance-1 (OXR1) and degrading it through the proteasome, raising oxidative stress specifically in senescent cells.[21] Structure–activity work confirmed the reactive Michael-acceptor group is required for this action.[22] This senolytic biology was shown in senescent fibroblasts, not in cancer cells; its oncology relevance — clearing the therapy-induced senescent cells that chemotherapy and radiotherapy can leave behind — is a reasonable extrapolation, not something these studies demonstrated.
ER stress & unfolded protein response (UPR)
HSP90 inhibitors have been reported to synergise with piperlongumine in colon cancer through oxidative-stress-driven ER stress (GRP78/ATF4/CHOP) and JNK activation, confirmed in xenografts and reversed by NAC.[23] In lung cancer, piperlongumine-induced ER stress suppressed pro-tumor M2 macrophage polarisation and inhibited syngeneic tumor growth.[24]
Piperlongumine's Attack classification rests on oxidative-stress-dependent regulated cell death — apoptosis and DNA damage across several xenograft-corroborated models, plus an emerging ferroptosis signal. As throughout, the effective concentrations are preclinical.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Piperlongumine has been reported to induce oxidative-stress-dependent mitochondrial apoptosis — PARP cleavage, caspase activation, loss of mitochondrial membrane potential — reversed by glutathione, with xenograft corroboration in pancreatic cancer (30 mg/kg/day, with PARP cleavage in the excised tumors),[6] head-and-neck cancer (caspase-7/-9 and PARP-1 activation; xenograft volume reduced at 4 mg/kg),[25] and gastric cancer (apoptosis and G2/M arrest in vitro and in vivo, abolished by NAC/glutathione).[26] In osteosarcoma it shifted the SMAD4/P21/P53 and Bcl-2/survivin axes toward death and synergised with doxorubicin.[35]
DNA damage & repair / PARP
Piperlongumine has been reported to raise oxidative DNA damage — γ-H2AX, comet-assay tail moment and the oxidative lesion 8-oxo-dG in head-and-neck cancer, abolished by NAC[25] — and to raise the 8-OHdG DNA-damage marker while suppressing pancreatic xenograft growth.[27]
Ferroptosis (execution / cell death)
A limited, emerging signal across two cancer models: piperlongumine has been reported to induce ferroptosis in oral squamous carcinoma — raising the lipid-peroxidation marker malondialdehyde and lowering the ferroptosis suppressors GPX4 and SLC7A11, with rescue by both a ferroptosis inhibitor and NAC[28] — and to inhibit glioblastoma growth in a xenograft through ferroptosis reversible by that same inhibitor.[29] It is treated as emerging because it rests on few studies and coexists with apoptosis in the same models.
Piperlongumine's Protect classification is scored on host-outcome evidence, not pathways. That evidence is preclinical only and genuinely mixed — two whole-animal studies report protection of normal tissue against chemotherapy toxicity, and a third reports no benefit — which is why the role is partial rather than active.
Oncology Host-Status
Cisplatin-induced peripheral neuropathy — in a mouse model, piperlongumine given after cisplatin has been reported to reduce thermal and cold pain sensitivity, lower inflammatory cytokines, and preserve sciatic-nerve axonal integrity on histology.[42]
Chemotherapy-associated cognitive impairment — in mice given a doxorubicin, cyclophosphamide and docetaxel regimen, co-treatment with piperlongumine has been reported to prevent the memory impairment seen with chemotherapy alone.[43]
A negative result, stated alongside — in the same chemotherapy regimen, piperlongumine used as a senolytic did not prevent chemotherapy-induced bone loss; none of the senolytics tested did.[44] This is included so the Protect signal is not read as a general tissue-protectant claim. A non-cancer anti-inflammatory finding and a non-cancer cardioprotection finding are excluded as outside cancer-care scope.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
Piperlongumine has been reported to shut down the NF-κB inflammatory-survival switch by binding its activating kinase directly, reducing tumor-supportive gene activity across prostate, breast and other cancer cells.
Redox Buffering Taxation (Controlled)
Research concerning tumour-cell redox buffering and vulnerability to oxidative pressure, separate from host redox protection.
NADPH production & redox balance
Piperlongumine's signature action is to disable the antioxidant enzymes cancer cells rely on to survive oxidative stress — GSTP1 and thioredoxin reductase 1 — tipping them past a lethal threshold that normal cells tolerate.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Piperlongumine has been reported to block STAT3, a survival-signaling hub, by binding it directly — with tumor-growth suppression in breast, lung and myeloma animal models.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Piperlongumine has been reported to trigger oxidative, mitochondrial cell death in pancreatic, head-and-neck and gastric cancer models — an effect reversed by antioxidants. Evidence is preclinical; concentration limitations apply.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
How piperlongumine moves through the body is, in humans, entirely unknown — there is no human pharmacokinetic study. What follows is built from rodent data and laboratory systems, and the single most important number on this page is one that has never been measured: the concentration piperlongumine reaches in a person.
Absorption
No human data exist. In mice, oral piperlongumine is absorbed and cleared quickly, reaching a total-plasma peak of about 2 µM at a low-milligram oral dose; a nanoemulsion roughly doubles that peak.
The Concentration Gap
Cancer cells are killed in the dish at roughly 4–15 µM. The only achievable-exposure figure — a mouse oral peak near 2 µM — already sits at or below that, and no human study exists to close the gap.
Clinical Dose Context
There is no established human oncology dose, because no cancer trial has been run. Retail piperlongumine is sold as a purified capsule, but no clinical basis supports any particular dose.
Formulation Effects
Piperlongumine is poorly water-soluble, most stable only near pH 4, and light-sensitive — which is why research and retail forms reach for lipid, nanoemulsion or liposomal delivery to raise how much is absorbed.
Metabolism
Human metabolism is uncharacterized. In liver enzymes, piperlongumine is broken down mainly by CYP1A2 and CYP3A4, forming a reactive epoxide metabolite of potential toxicological interest.
Co-Dosing Considerations
Two directions of interaction: antioxidants such as N-acetylcysteine can switch off piperlongumine's mechanism, and it may raise the exposure of drugs cleared by CYP3A4, P-glycoprotein or CYP1A2.
Absorption
No human pharmacokinetic study of piperlongumine exists, so nothing below describes a person. In mice, oral piperlongumine is absorbed rapidly and cleared quickly: after a 10 mg/kg oral dose the peak plasma concentration of free piperlongumine was about 659 ng/mL — roughly 2 µM, given its molecular weight near 317 g/mol — at a Tmax of 10 minutes, with an elimination half-life of about 87 minutes and a relative oral bioavailability near 69%.[3] A lipid nanoemulsion roughly doubled the peak concentration and raised oral bioavailability toward 90–98%[3] — the entire commercial rationale for the enhanced-delivery forms covered under Formulation Effects below.
The Concentration Gap
This is the load-bearing pharmacokinetic fact, and it has to be framed around the absence of human data. In-vitro cytotoxic concentrations cluster in the low-micromolar range — roughly 4 to 15 µM across the cell studies behind the Pathway Interaction Profile above. The best available exposure figure is from mice: a total-plasma oral peak of about 2 µM at 10 mg/kg — measured after a solubilized formulation, not a plain powder — already at or below most of those effective concentrations.[3] Read this as an exposure warning, not a demonstrated quantitative gap: the culture figures are nominal media concentrations, the mouse figure is total (largely protein-bound, about 93%) plasma drug rather than free or tumor-tissue drug, and no human data exist to resolve the difference. What it does establish is that the available animal PK gives no reason to assume oral human exposure could reproduce the concentrations used in cells.[5]
| Benchmark | Concentration | Interpretation |
|---|---|---|
| Concentration that kills cancer cells in vitro | ~4–15 µM | The range across the head-and-neck, oral and other cell studies underlying the pathways above[1,28] |
| Free piperlongumine peak — mouse, 10 mg/kg oral | ~2 µM | Total plasma drug after a solubilized oral dose in mice — not free, tumor-tissue, or human exposure; already at or below the effective range[3] |
| Any human plasma concentration | Not measured | No human pharmacokinetic study exists, so the gap for oral human use cannot be quantified[5] |
Clinical Dose Context
There is no clinical dose context to give, because no interventional cancer trial has been run and no human oncology dose has ever been established. Retail piperlongumine is sold in purified capsules, but any such dose reflects a manufacturing choice, not a studied one — there is no human evidence for what dose, if any, reaches a meaningful concentration in a person, and no registered trial doses it as a drug.[39] Every dose figure elsewhere on this page is an animal dose, given by injection in most of the studies that reported efficacy.
Formulation Effects
Piperlongumine is chemically awkward to deliver. It is poorly water-soluble (aqueous solubility around 26 µg/mL), most stable only near pH 4, significantly unstable at pH 7 or above, and photolabile in aqueous media; a surfactant such as 10% polysorbate-80 raised its solubility 27-fold.[31] These constraints are the reason research and retail forms use lipid, nanoemulsion or liposomal delivery — strategies that improved both exposure and potency versus free piperlongumine in animals,[3] though none has been validated in humans.
| Property | Finding | Why it matters |
|---|---|---|
| Water solubility | ~26 µg/mL | Very low — a plain powder dissolves poorly, limiting how much can be absorbed[31] |
| Chemical stability | Best near pH 4 | Unstable at neutral/alkaline pH and in light, so an unprotected form degrades[31] |
| Nanoemulsion delivery | ~90–98% oral F (mouse) | Raised oral bioavailability and potency versus free compound in mice — not tested in humans[3] |
Metabolism
Human metabolism is uncharacterized — a dedicated study states outright that no study of piperlongumine's metabolism in the human body exists. In human liver microsomes it is oxidized chiefly by CYP1A2 and CYP3A4, forming four metabolites including a reactive lactam-ring epoxide; its hepatic extraction ratio is low (0.09) and plasma protein binding is high (about 93%).[5] Rat-liver-microsome work independently showed cooperative CYP-mediated conversion to hydroxylated metabolites.[32]
Co-Dosing Considerations
No human pharmacokinetic drug-interaction study for piperlongumine exists. The rows below rest on laboratory human-tissue and animal data, and each is flagged by the most cautious guidance that evidence supports. One of them is unusual: because piperlongumine works by raising oxidative stress, antioxidant supplements can switch its mechanism off.
Discuss whether to combine, separate, or avoid piperlongumine and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Caution | Thiol antioxidants and glutathione donors — N-acetylcysteine most clearly — functionally antagonise piperlongumine: because its cytotoxicity is oxidative-stress-driven, pre-treating cells with these agents abolished it in the laboratory. High-dose antioxidant supplements taken alongside it could blunt its intended effect.[1,34] |
| Caution | Medicines cleared by CYP3A4 or pumped by P-glycoprotein warrant clinician review: in the laboratory piperlongumine inhibited CYP3A4-mediated metabolism by about half and reduced P-glycoprotein efflux, raising oral docetaxel exposure roughly 1.7-fold in rats — so it could raise the exposure, and toxicity, of such drugs, including some chemotherapy agents. No human interaction has been demonstrated.[33] |
| Caution | Immunotherapy and immunosuppressant regimens warrant discussion: in primary human T cells piperlongumine suppressed effector T-cell activation and shifted the balance toward regulatory T cells, raising a theoretical concern that it could blunt anti-tumor immunity or immune-checkpoint therapy.[40] The direction is genuinely uncertain, though: in an immunocompetent glioblastoma model, piperlongumine added to radiotherapy and temozolomide instead increased tumor-infiltrating CD8 T cells and improved survival, with an anti-PD-1 antibody adding further benefit.[49] Neither result has been tested clinically. |
| Monitor | Narrow-therapeutic-index medicines cleared by CYP1A2 warrant monitoring: piperlongumine inhibited CYP1A2 in the laboratory, both reversibly and in a mechanism-based way, so it could in principle raise their levels. No human interaction magnitude has been established.[5] |
Advertisement
04 — Onset & Washout
Onset and Washout
Piperlongumine's timing has never been measured in a person. What can be described is a fast plasma clock in mice and a slow phenotypic clock in animal tumor studies — and, importantly, nothing connecting the two, or connecting either to a human.
Immediate Onset
In mice, free piperlongumine peaks within about ten minutes of an oral dose and is largely cleared within hours. This describes mouse plasma concentration only — there is no human measurement.
Steady State
No repeated-dose pharmacokinetic study exists in any species at the depth needed to describe steady-state exposure, accumulation, or continuous target engagement.
Accumulated Effect
Animal antitumor studies dosed daily for roughly two to three weeks before measuring an effect. No human course has been run, and no pulsed schedule has been tested.
Dosing Pattern in Studies
Effective animal studies used daily dosing, and in most of them the compound was injected rather than given by mouth. That describes how it was studied, not a recommended regimen.
Washout
How long piperlongumine's influence might take to clear before it stops being a relevant factor for co-administered medications.
No washout period exists. With no human pharmacokinetics, no metabolite-disposition data, and a mechanism-based enzyme inhibition whose duration is unmeasured, no interval can be calculated.
Two Distinct Clocks
Piperlongumine's timeline splits into two genuinely different layers: how quickly the compound appears in and leaves the blood, and how long a tumor-relevant change takes to show up in an animal study. Neither has been measured in a person, and no measurement connects the two — so read both clocks as descriptive, not as a schedule.
Clock A — Measured Plasma Exposure — tracks the compound itself. In mice, free piperlongumine peaked within about ten minutes of an oral dose and cleared quickly, with an elimination half-life near 1.4 hours.[3] That describes mouse plasma concentration only. A short plasma half-life does not establish that the compound's effect on its targets ends at the same time, that tissue concentrations track plasma, or — most importantly — that anything similar happens in a human, since no human pharmacokinetic study exists.
| Clock A — Measured Plasma Exposure | Clock B — Downstream Phenotypic Effect | |
|---|---|---|
| Onset | Fast — mouse plasma piperlongumine peaks within about ten minutes of an oral dose | Slow — measurable tumor changes needed roughly two to three weeks of daily dosing in the animal studies |
| Persistence | Short — mouse elimination half-life near 1.4 hours | Sustained — every antitumor study used repeated daily dosing, not single doses |
| What it covers | Mouse plasma concentration only — not target engagement, tissue levels, or anything measured in a human | Animal tumor-growth readouts under the studied, repeated-dosing regimens — not a human outcome |
Clock B — Downstream Phenotypic Effect — is what the animal studies measured. Tumor-growth suppression was recorded after roughly two to three weeks of daily dosing — for example 30 mg/kg/day for three weeks in a pancreatic model,[6] and 30 mg/kg/day for two weeks in a breast model.[18] No study tested a single dose or a pulsed schedule, and none measured how the plasma clock connects to the phenotypic one — only that sustained, repeated dosing is what produced the effect in animals.
Steady State and Accumulation
Not established. There is no repeated-dose human pharmacokinetic study — and no depth animal study — confirming steady-state plasma levels, accumulation, trough concentrations, or continuous target engagement. What the studies establish is narrower: every antitumor regimen used repeated daily dosing in animals. That supports daily administration as the studied pattern; it does not prove daily dosing is biologically necessary to sustain a pathway-level effect, and it says nothing about a human.
Dosing Pattern in Studies
Every antitumor study that reported an effect used repeated, continuous daily dosing over days to weeks, and in most of them piperlongumine was given by injection rather than orally. None tested a pulsed or single-dose schedule, so there is no direct evidence for how the phenotypic effect relates to the plasma pattern — only that sustained, repeated dosing is what produced the animal results.
Piperlongumine is therefore best described as studied under daily, continuous dosing in animals for the settings it has actually been tested in — not because a pulsed approach has been shown to fail, but because it simply has not been tested, and because none of it has been studied in a person. For what a mechanistically meaningful concentration would require, see The Concentration Gap under Pharmacokinetics and Administration.
Washout
No washout period for piperlongumine has been established. The mouse pharmacokinetic data describe plasma elimination in a different species, and the drug-interaction evidence under Co-Dosing Considerations comes from laboratory systems — it does not establish a human interaction magnitude or measure how long enzyme inhibition would persist. A plasma half-life cannot be used to calculate an enzyme-interaction washout period, since interaction duration can depend on active metabolites, intracellular retention, whether inhibition is reversible or mechanism-based, enzyme turnover, and repeated dosing — none of which has been measured for piperlongumine in a person. No washout interval is recommended here.
Advertisement
05 — Safety
Safety Profile
Piperlongumine has no human safety record — no cancer trial has been run, so there is no adverse-event, tolerability, or liver-injury data in people. What adverse signals exist are preclinical: a positive developmental-toxicity signal in fish embryos, an off-target effect on human immune cells, a mammalian genotoxicity signal, and a theoretical liver concern from a reactive metabolite.
No human safety data — because no clinical trial has been run, there is no adverse-event, tolerability, or liver-injury record for piperlongumine in people.
Positive developmental-toxicity signal — piperlongumine caused abnormal development in fish embryos at concentrations overlapping the mouse plasma range; avoidance in pregnancy is prudent.
Off-target effect on human immune cells — it suppressed effector T-cell activation in the laboratory, a genuine finding in human cells with implications discussed under Co-Dosing.
Mammalian genotoxicity signal — negative in bacteria, but positive chromosome-aberration and micronucleus results in mammalian cells, and in mice at a high dose.
Adverse Effects and Preclinical Tolerability
There are no human adverse-event data. In the animal data that exist, piperlongumine was well tolerated: a 60-day oral course at 10 mg/kg in mice produced no weight change, normal liver and kidney blood panels, and no histopathological organ damage,[3] and a separate study dosed aged mice at 50 mg/kg orally for eight weeks with no reported adverse effect.[46] Antitumor studies routinely reported no significant body-weight loss at effective doses. The one laboratory-level caution is a theoretical hepatotoxicity signal: piperlongumine forms a reactive epoxide metabolite and mechanism-based-inactivates the liver enzyme CYP1A2, either of which could in principle stress the liver — an inference from enzyme studies, not an observed injury.[5]
Genotoxicity in Mammalian Systems
Piperlongumine's oxidative mechanism cuts both ways for safety. In genotoxicity testing, piplartine was non-mutagenic in bacteria (the Ames test was negative), but it caused chromosome aberrations and micronuclei in cultured mammalian (V79) cells, and produced a positive bone-marrow micronucleus signal in mice at 100 mg/kg — though not at the lower 50 mg/kg dose.[47] This does not establish a clinically relevant risk: the positive in-vivo result was at a high dose, and the finding has not been followed up in humans. But for a compound whose intended action is oxidative DNA damage in cancer cells, a positive genotoxicity signal in non-tumor mammalian systems belongs on the record rather than being left out.
Immunosuppression of Human T Cells
In primary human T cells, piperlongumine has been reported to suppress effector T-cell activation — blocking immune-synapse formation, activation-marker upregulation, proliferation and cytokine release — and to shift CD4 differentiation toward regulatory T cells, through the same oxidative mechanism it uses against tumor cells, with the effects abolished by antioxidants.[40] This is one of the few piperlongumine findings in human cells. It is an off-target effect rather than a classic adverse event, and its practical concern — a possible blunting of anti-tumor immunity or immunotherapy — is covered under Co-Dosing above, where a contradictory tumor-context result (increased CD8 T-cell infiltration in an animal model) is noted alongside it.
Developmental and Reproductive Safety
The one developmental-toxicity study that exists is positive: in zebrafish embryos, piperlongumine caused abnormal heart and yolk-sac development and developmental delay at 1–2.5 µM, with acute toxicity at 5–10 µM.[45] A fish embryo is not a mammal and these concentrations do not quantify a human risk, but a positive developmental-toxicity result is enough on its own to justify caution. No mammalian testicular, sperm or fertility study was found in the literature reviewed — the mammalian reproductive question is a genuine data gap. Given the positive developmental signal and that gap, use in pregnancy or when trying to conceive should be avoided unless specifically reviewed by a qualified clinician.
06 — Sourcing
Sourcing Guide
Formulation is the biggest factor in whether a piperlongumine product could deliver anything close to what the research above describes — the compound is poorly water-soluble, chemically unstable, and light-sensitive, so purity and a protective delivery form matter more here than for most compounds. Our Sourcing Guide covers products available on the retail market against those concerns.
Piperlongumine Sourcing Guide07 — Literature
References
Last reviewed: August 2026